PKIS v2.0 A clinical tool for identifying important pharmacokinetic drug-drug interactions
Contributors

Flinder's University, Adelaide

Matt Doogue
Clinical Pharmacologist
Department of Clinical Pharmacology
Thomas Polasek
Lecturer
Department of Clinical Pharmacology

The University of New South Wales, Sydney

Frank Lin
Post-doctoral fellow
Centre for Health Informatics
Citing PKIS
Please cite PKIS as:
Polasek TM, Lin FP, Miner JO, Doogue MP. Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochorome P450 activity: a criteria-based assessment. Br J Clin Pharmacol 2011; 71(5): 727-736.
Related publications
  1. Polasek TM and Doogue MP (2008) A criteria based catalogue of clinically important cytochrome P450 inhibitors and inducers. Proceedings of the Australian Health and Medical Research Congress 2008, Abstract 861, p. 426.
  2. Polasek TM and Doogue MP (2009) Important inhibitors and inducers of cytochrome P450 enzymes: what is the clinical evidence? Conference Handbook and Book of Abstracts: 35th Society of Hospital Pharmacists of Australia National Conference, Poster 185, p. 215.
  3. Deacon PM, Griffith-Jones T, Polasek TM, Mangoni AA, and Doogue MP (2009) Screening for potential drug-drug interactions by intern doctors: a survey of clinical practice. Proceedings: Australasian Society of Clinical and Experimental Pharmacologists, vol. 14, Poster 1-4.
  4. Doogue MP and Polasek TM (2009) Simplifying the evaluation of potential drug-drug interactions. Proceedings: Australasian Society of Clinical and Experimental Pharmacologists, vol. 14, Oral 68.
  5. Doogue MP, Polasek TM, and Lin F (2010) Prescriber evaluation of potential drug-drug interactions, room for improvement? Internal Medicine Journal, vol. 40, suppl. 1, p. 14-15.
  6. Miners JO, Doogue MP, and Polasek TM (2010) Taming drug-drug interactions. National Medicines Symposium 2010, Abstract 177, p. 118
  7. Polasek TM, Lin FP, Miner JO, and Doogue MP. Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochorome P450 activity: a criteria-based assessment. British Journal of Clinical Pharmacology. 2011; 71(5): 727-736.
  8. Lin FP, Anthony S, Polasek TM, Tsafnat G, Doogue MP. BICEPP: an example-based statistical text mining method for predicting the binary characteristics of drugs. BMC Bioinformatics 2011, 12:112
Data sources

Drug lists

  • Australian Medicines Handbook (AMH 2009) (ISBN: 978-0-9757919-9-8)
  • eMIMS (Version 5.01.0097, CMPMedica Australia Pty Ltd)
  • Cytochromes P450 Drug Interaction Table (CDIT) (Version 5.0)
    • Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. Journal of Pharmacology & Experimental Therapeutics. 2006;316(1):336-348
  • the Preferred Medicines List 11th edition (Canterbury District Health Board) (ISBN: 0-473-08171-7)

Literature and drug information databases

Disclaimer
WARNING: While all efforts were put in to maintain the accuracy and currency of the information, it is possible that the knowledge and electronic tools may contain errors and inadequacy. Both Flinder's University and University of New South Wales are not liable to any damages or losses resulted from such circumstances. Clinical discretions are strongly advised at all times.